Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, DUGGAN ROBERT W, holds the title of Co-Chief Executive Officer at Summit Therapeutics Inc..
On 2026-11-20, the insider transacted 300,000 shares.The shares were transacted at a weighted average price of $1.06 per share, resulting in a total market-relevant value of $318K.
DUGGAN ROBERT W (Co-Chief Executive Officer) exercised options for $318K of $SMMT
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.